TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04015856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full TP intervention
Description: CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light TP intervention
Description: The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
Study: NCT03281837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS plus Physical Exercise Program (PEP)
Description: 1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)

Intervention type: DEVICE
Group type: OTHER
Intervention: HYMOVIS plus Physical Exercise Program (PEP)
Description: 1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Exercise Program (PEP) alone
Description: Physical Exercise Program (PEP) alone for at least 8 weeks
Study: NCT03741933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg tablet
Study: NCT03758287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Study: NCT01434615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT
Description: Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-CRT
Description: Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
Study: NCT04441892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTc Meter
Description: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTc Meter
Description: Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.
Study: NCT02545985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolim stent deployment
Description: Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
Study: NCT01849991

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
Study: NCT04286945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LATERAL RECTUS MUSCLE AUGMENTED RECESSION BY ELONGATION OF THE TENDON WITH AUTOGRAFT FROM RESECTED MEDIAL RECTUS MUSCLE
Description: After resection of the medial rectus muscle, the resected segment is sutured to the lateral rectus muscle after dissection and marking to elongate and slaken the muscle then the elongated muscle is sutured to the sclera at the desired amount of conventional recession.
Study: NCT02546271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GPS
Study: NCT00267059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg/day, orally once a day for 28 days
Study: NCT01173367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Fever Treatment
Description: Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Permissive Fever Treatment
Description: Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
Study: NCT01232023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Single Oral Dose of

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Single Oral Dose of
Study: NCT03839160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous patient-controlled-analgesia morphine
Description: Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient-controlled-analgesia morphine
Description: Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
Study: NCT00549835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real Acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Real Acupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility.
Study: NCT00936767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisone/Mefloquine (AmiM3)
Description: Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
Study: NCT01501565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative transverse abdominal plain (TAP) blockade
Description: Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
Study: NCT01735006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: 3 doses at month 0,1 and 6

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HEV vaccine
Description: 3 doses at month 0,1 and 6
Study: NCT02960581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 3mg/kg IV
Description: 3mg/kg administered by IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 3mg/kg IV
Description: 3mg/kg administered by IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 10mg/kg IV
Description: 10mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 10mg/kg IV
Description: 10mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 30mg/kg IV
Description: 30mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 30mg/kg IV
Description: 30mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 30mg/kg IV
Description: 30mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 30mg/kg IV
Description: 30mg/kg administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121 3mg/kg SC
Description: 3mg/kg administered by SC injection~Placebo: None

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% Sodium Chloride Injection USP (Saline))
Study: NCT03762057

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraabdominal pressure monitoring
Description: Classic manometry technique measurement once daily
Study: NCT04363970

Intervention type: OTHER
Intervention: removal of the urinary catheter
Description: in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.

Intervention type: OTHER
Intervention: removal of the urinary catheter
Description: in group A, we will remove the catheter after 24 h. In group B, we will remove the catheter after 48 h.
Study: NCT02341183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPAD
Description: 7% NaCl administered continuously for 8 hours, overnight, via the tPAD device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPAD
Description: 7% NaCl administered continuously for 8 hours, overnight, via the tPAD device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7% hypertonic saline (510K approved as a device)
Description: Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7% hypertonic saline (510K approved as a device)
Description: Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
Study: NCT00674817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 microgrammes GSK961081
Description: Inhaled GSK961081 administered via Dry Powder Inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1200 microgrammes GSK961081
Description: Inhaled GSK961081 adminisntered via dry powder inhaler.
Study: NCT01958372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo RT
Study: NCT01939613

Intervention type: DRUG
Intervention: colloids
Description: TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
Study: NCT01582893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO1100
Description: Dialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P210H
Description: Dialysis
Study: NCT04617626

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Single dose of azithromycin suspension
Study: NCT01112917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaTech Convertible Vena Cava Filter
Description: Prevention of Pulmonary Embolism

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vena Cava Filter Conversion
Description: Conversion of VenaTech Convertible filter to open configuration.
Study: NCT00815659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Study: NCT01912170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Study: NCT01216826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
Study: NCT04138797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological exploration
Description: Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Biosemi
Description: Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
Study: NCT00755651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Description: Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
Study: NCT03035266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Standard of care for post-operative condition
Study: NCT02894112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-fat milk
Description: 1 serving of non-fat fluid milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-fat milk
Description: 1 serving of non-fat fluid milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate control beverage
Description: 1 serving of carbohydrate control beverage (Carbohydrate powder + water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate control beverage
Description: 1 serving of carbohydrate control beverage (Carbohydrate powder + water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caloric control beverage
Description: 1 serving of caloric control beverage (carbohydrate powder + protein powder + water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caloric control beverage
Description: 1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
Study: NCT01178671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
Study: NCT00573885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally